Patients with NSCLC and CIP had higher BMI values pre-neoadjuvant therapy (pre-BMI) (24.1 ± 3.1 vs. 22.7 ± 3.2 kg/m2, p = 0.028) and higher CRP levels post-neoadjuvant therapy (5.6 [3.1–16.1] vs. 3.8 [1.9–6.6] mg/L, p = 0.029). The gene discussed is CRP; the disease is non-small cell lung carcinoma.